About basilea pharmaceutica ag - BPMUF
Basilea Pharmaceutica AG engages in the discovery, development, and commercialization of pharmaceutical products. Its products include antifungals and antibiotics. The company was founded on October 17, 2000 and is headquartered in Allschwil, Switzerland.
BPMUF At a Glance
Basilea Pharmaceutica AG
Hegenheimermattweg 167b
Allschwil, Basel-Landschaft (Basle Country) 4123
| Phone | 41-61-606-11-11 | Revenue | 279.81M | |
| Industry | Pharmaceuticals: Major | Net Income | 48.45M | |
| Sector | Health Technology | 2025 Sales Growth | 18.163% | |
| Fiscal Year-end | 12 / 2026 | Employees | 189 | |
| View SEC Filings |
BPMUF Valuation
| P/E Current | 16.996 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 17.442 |
| Price to Sales Ratio | 3.377 |
| Price to Book Ratio | 5.255 |
| Price to Cash Flow Ratio | 12.64 |
| Enterprise Value to EBITDA | 12.813 |
| Enterprise Value to Sales | 3.047 |
| Total Debt to Enterprise Value | 0.132 |
BPMUF Efficiency
| Revenue/Employee | 1,480,486.671 |
| Income Per Employee | 256,367.948 |
| Receivables Turnover | 3.503 |
| Total Asset Turnover | 0.874 |
BPMUF Liquidity
| Current Ratio | 5.115 |
| Quick Ratio | 4.677 |
| Cash Ratio | 3.298 |
BPMUF Profitability
| Gross Margin | 83.078 |
| Operating Margin | 22.182 |
| Pretax Margin | 19.741 |
| Net Margin | 17.316 |
| Return on Assets | 15.133 |
| Return on Equity | 38.629 |
| Return on Total Capital | 17.677 |
| Return on Invested Capital | 20.112 |
BPMUF Capital Structure
| Total Debt to Total Equity | 69.733 |
| Total Debt to Total Capital | 41.084 |
| Total Debt to Total Assets | 31.637 |
| Long-Term Debt to Equity | 68.121 |
| Long-Term Debt to Total Capital | 40.134 |